Clinical Trial Update: A Safety, Tolerability and Pharmacokinetic Study of LEO 29102 in Subjects With Atopic Dermatitis [Phase 1]

View source ↗

Summary

Phase 1 safety, tolerability and pharmacokinetic study of LEO 29102 in subjects with atopic dermatitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• LEO 29102

Snippet

Sponsor: LEO Pharma | Conditions: Atopic Dermatitis | Phase 1 | Status: COMPLETED